Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | ANPEP | P15144 | 2/20 | 0.41 |
| ▸ | IL1RN | P18510 | 1/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.41 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8817005 | 0.79 | MAOA (0.55) | ANPEPIL1RNERAP2ERAP1MAOA | |
| SCHEMBL27923062 | 0.74 | DRD2 (0.33) | AKR1B1ANPEPIL1RNERAP2ERAP1 | |
| SCHEMBL5539477 | 0.73 | AKR1B1 (0.45) | AKR1B1MAOAMAOB | |
| SCHEMBL29405055 | 0.72 | MAOA (0.54) | AKR1B1MAOAMAOBBCHECES1 | |
| SCHEMBL149855 | 0.72 | MAOA (0.54) | AKR1B1MAOAMAOBBCHECES1 | |
| SCHEMBL13495858 | 0.72 | AKR1B1 (0.44) | AKR1B1 | |
| SCHEMBL32672943 | 0.72 | AKR1B1 (0.44) | AKR1B1MAOAMAOB | |
| SCHEMBL5539483 | 0.72 | MEN1 (0.47) | AKR1B1MAOAMAOB | |
| SCHEMBL3520803 | 0.72 | AKR1B1 (0.44) | AKR1B1MAOAPIM1MAOB | |
| SCHEMBL2807475 | 0.71 | AKR1B1 (0.41) | AKR1B1MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230117370-A1 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2023-04-20 | — | — | US | disclosed |
| WO-2021211982-A2 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | OREGON STATE UNIVERSITY (US) | 2021-10-21 | — | — | WO | disclosed |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117370-A1 | REGIOSELECTIVE SYNTHESIS OF SUBSTITUTED COMPOUNDS | CYP2B6, TYR, CYP2D6 | AKR1B1 1363/4885ANPEP 3146/4885IL1RN 4810/4885 |
| US-20170182010-A1 | BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS | ASAH1, ASAH2, ACER2 | AKR1B1 1171/4885ANPEP 517/4885IL1RN 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.